U Darsow1, M Sbornik2, S Rombold2, K Katzer2, F von Sonnenburg3, H Behrendt2, J Ring2. 1. Department of Dermatology and Allergy Biederstein, Technical University of Munich (TUM) and ZAUM - Center of Allergy and Environment, Munich, Germany. ulf.darsow@tum.de. 2. Department of Dermatology and Allergy Biederstein, Technical University of Munich (TUM) and ZAUM - Center of Allergy and Environment, Munich, Germany. 3. Department of Infectious Diseases and Tropical Medicine, Ludwig-Maximilian-University, Munich, Germany.
Abstract
BACKGROUND: Availability of a safe smallpox vaccine may be necessary under certain circumstances. Use of the old life virus vaccine was associated with serious adverse events, particularly in the setting of atopic eczema (AE) and immunodeficiency. Modified virus Ankara (MVA)-BN, a highly attenuated strain of vaccinia virus, was developed for vaccination with improved safety profile. METHODS: A phase 1 study was conducted in 60 subjects without history of smallpox vaccination to gain experience with smallpox vaccination using this strain in healthy and atopic subjects. Healthy subjects, subjects with a history of AE, subjects with mild active AE and subjects with mild allergic rhinitis without AE were equally allocated into four groups. MVA-BN was injected s.c. in a dose of 108 TCID50 twice in a 4-week interval. RESULTS: No serious or unexpected adverse reactions were reported. All subjects experienced mild to moderate pain and redness at the injection site. Dermatologic examinations did not reveal any unfavourable reactions to the study medication, particularly no sign or exacerbation of eczema for as long as 196 days. All subjects seroconverted after two vaccinations and no significant difference in antibody titres between the four different groups was observed. CONCLUSIONS: A good safety profile of the MVA-BN vaccine was shown. The absence of adverse events in subjects with atopic disorders appears promising for the development of a safe smallpox vaccine for patients with AE or other atopic diseases.
BACKGROUND: Availability of a safe smallpox vaccine may be necessary under certain circumstances. Use of the old life virus vaccine was associated with serious adverse events, particularly in the setting of atopic eczema (AE) and immunodeficiency. Modified virus Ankara (MVA)-BN, a highly attenuated strain of vaccinia virus, was developed for vaccination with improved safety profile. METHODS: A phase 1 study was conducted in 60 subjects without history of smallpox vaccination to gain experience with smallpox vaccination using this strain in healthy and atopic subjects. Healthy subjects, subjects with a history of AE, subjects with mild active AE and subjects with mild allergic rhinitis without AE were equally allocated into four groups. MVA-BN was injected s.c. in a dose of 108 TCID50 twice in a 4-week interval. RESULTS: No serious or unexpected adverse reactions were reported. All subjects experienced mild to moderate pain and redness at the injection site. Dermatologic examinations did not reveal any unfavourable reactions to the study medication, particularly no sign or exacerbation of eczema for as long as 196 days. All subjects seroconverted after two vaccinations and no significant difference in antibody titres between the four different groups was observed. CONCLUSIONS: A good safety profile of the MVA-BN vaccine was shown. The absence of adverse events in subjects with atopic disorders appears promising for the development of a safe smallpox vaccine for patients with AE or other atopic diseases.
Authors: Frank von Sonnenburg; Pamela Perona; Ulf Darsow; Johannes Ring; Alfred von Krempelhuber; Jens Vollmar; Siegfried Roesch; Nicole Baedeker; Herwig Kollaritsch; Paul Chaplin Journal: Vaccine Date: 2014-08-20 Impact factor: 3.641
Authors: Michael D Howell; James F Jones; Kevin O Kisich; Joanne E Streib; Richard L Gallo; Donald Y M Leung Journal: J Immunol Date: 2004-02-01 Impact factor: 5.422
Authors: Ranjit Sah; Abdelaziz Abdelaal; Abdullah Reda; Basant E Katamesh; Emery Manirambona; Hanaa Abdelmonem; Rachana Mehta; Ali A Rabaan; Saad Alhumaid; Wadha A Alfouzan; Amer I Alomar; Faryal Khamis; Fadwa S Alofi; Maha H Aljohani; Amal H Alfaraj; Mubarak Alfaresi; Jumana M Al-Jishi; Jameela Alsalman; Ahlam Alynbiawi; Mohammed S Almogbel; Alfonso J Rodriguez-Morales Journal: Pathogens Date: 2022-08-17